Sweden's Biovica Q4 sales double, helping net loss narrow
Sweden's Biovica Q4 sales double, helping net loss narrow
Overview
Sweden cancer biomarker firm's fiscal Q4 net sales more than doubled year-on-year
Company's Q4 net loss narrowed from a year earlier
Biovica sharpened commercial focus and appointed new CEO as part of next growth phase
Outlook
Company aims to accelerate adoption of DiviTum TKa and broaden its use in the new fiscal year
Biovica plans to prioritize markets and partnerships with greatest product adoption and revenue growth potential
Company to focus on efficiency, financial discipline, and improved cash flow in next commercial phase
Result Drivers
PHARMA SERVICES DEMAND - Strong demand in Pharma Services driven by need for validated biomarkers and regulatory focus on dose optimization
U.S. ADOPTION - Growing commercial adoption of DiviTum TKa in the U.S. contributed to sales growth
Company press release: ID:nMFN1Ljm3K
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales |
| SEK 4.82 mln |
|
Q4 EPS |
| -SEK 0.07 |
|
Q4 Net Income |
| -SEK 19.12 mln |
|
Q4 Operating profit |
| -SEK 18.04 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Biovica International AB is SEK0.70, about 122.2% above its June 16 closing price of SEK0.32
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)